Vasomedical Introduces Policy Makers Focusing on Healthcare Reform to EECP® Therapy
April 16th, 2013 Wall Street Journal (full article)
Vasomedical, Inc. a worldwide leader in Enhanced External Counterpulsation Therapy (EECP) devices has recently made an effort to contact a group of Congressmen seasoned in the medical field to introduce EECP Therapy as a treatment option to reduce costs to the U.S healthcare system. EECP Therapy is a treatment that has demonstrated in nearly 200 published clinical research trials to be a being safe, cost effective treatment option that has been documented to lower re-hospitalizations & repeated emergency room visits for patients suffering from ischemic cardiovascular disease. This effort marks a significant breakthrough in the industry as EECP has long been overlooked as an effective solution to battle the substantial financial burden of patients with advanced heart disease.
It is known in the U.S that the annual expenditures for healthcare services exceeds $2.6 trillion (about 18 percent of gross domestic product). With such a significant burden, it is only logical to introduce new medical therapies that can successfully improve patient management while simultaneously lowering costs. With the Affordable Care Act underway, this a top priority for Senators and Representatives focusing on healthcare reform in Washington, D.C.
EECP Therapy systems are designed to increase blood flow to the coronary arteries and reduce the workload of the heart. This hemodynamic treatment works like passive exercise to increase blood flow to the heart and improve endothelial function throughout the cardiovascular system, and, most importantly, it has been proven to be clinically effective. Clinical studies published in peer reviewed medical journals demonstrate that patients who have undergone this treatment experience an elimination or significant reduction in symptoms, a reduction in major adverse cardiac events, re-hospitalizations and emergency room visits, as well as a greatly improved quality of life.
Vasomedical reached out to these select policy makers who have a vested interest in healthcare reform to educate them about alternative treatments to typical invasive and costly methods and the positive impact it could have on our current healthcare system. The objective is to increase awareness of this technology and its implications among policy members to make EECP service available to cardiac patients as a low risk, clinically effective, solution at a much lower cost to the U.S healthcare system.
